Literature DB >> 19167135

CoMFA and docking studies of 2-phenylindole derivatives with anticancer activity.

Si Yan Liao1, Li Qian, Ti Fang Miao, Hai Liang Lu, Kang Cheng Zheng.   

Abstract

Three-dimensional (3D) quantitative structure-activity relationship (QSAR) and docking studies of 43 tubulin inhibitors, 2-phenylindole derivatives with anticancer activity against human breast cancer cell line MDA-MB 231, have been carried out. The established 3D-QSAR model from the comparative molecular field analysis (CoMFA) in training set shows not only significant statistical quality, but also satisfying predictive ability, with high correlation coefficient value (R(2)=0.910) and cross-validation coefficient value (q(2)=0.705). Moreover, the predictive ability of the CoMFA model was further confirmed by a test set, giving the predictive correlation coefficient (R(2)(pred)) of 0.688. Based on the CoMFA contour maps and docking analyses, some key structural factors responsible for anticancer activity of this series of compounds were revealed as follows: the substituent R(1) should have higher electronegativity; the substituent R(2) should be linear alkyl with four or five carbon atoms in length; and the substituent R(3) should be selected to OCH(3)-kind group whereas should not be selected to CF(3)-kind group. Meanwhile, the interaction information between target and ligand was presented in detail. Such results can offer some useful theoretical references for understanding the action mechanism, designing more potent inhibitors and predicting their activities prior to synthesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19167135     DOI: 10.1016/j.ejmech.2008.12.020

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

1.  QM/MM based 3D QSAR models for potent B-Raf inhibitors.

Authors:  Jae Yoon Chung; Hwan Won Chung; Seung Joo Cho; Jung-Mi Hah; Art E Cho
Journal:  J Comput Aided Mol Des       Date:  2010-04-01       Impact factor: 3.686

2.  In silico prediction of estrogen receptor subtype binding affinity and selectivity using statistical methods and molecular docking with 2-arylnaphthalenes and 2-arylquinolines.

Authors:  Zhizhong Wang; Yan Li; Chunzhi Ai; Yonghua Wang
Journal:  Int J Mol Sci       Date:  2010-09-20       Impact factor: 5.923

3.  Combined 3D-QSAR and Docking Modelling Study on Indolocarbazole Series Compounds as Tie-2 Inhibitors.

Authors:  Yuanxin Tian; Jian Xu; Zhonghuang Li; Zhengguang Zhu; Jiajie Zhang; Shuguang Wu
Journal:  Int J Mol Sci       Date:  2011-08-10       Impact factor: 5.923

4.  The three dimensional Quantitative Structure Activity Relationships (3D-QSAR) and docking studies of curcumin derivatives as androgen receptor antagonists.

Authors:  Guanhong Xu; Yanyan Chu; Nan Jiang; Jing Yang; Fei Li
Journal:  Int J Mol Sci       Date:  2012-05-18       Impact factor: 6.208

5.  CoMFA, CoMSIA, HQSAR and Molecular Docking Analysis of Ionone-based Chalcone Derivatives as Antiprostate Cancer Activity.

Authors:  R Sharma; N Dhingra; S Patil
Journal:  Indian J Pharm Sci       Date:  2016 Jan-Feb       Impact factor: 0.975

6.  Enhanced Biodegradation of Phthalic Acid Esters' Derivatives by Plasticizer-Degrading Bacteria (Burkholderia cepacia, Archaeoglobus fulgidus, Pseudomonas aeruginosa) Using a Correction 3D-QSAR Model.

Authors:  Haigang Zhang; Chengji Zhao; Hui Na
Journal:  Int J Environ Res Public Health       Date:  2020-07-23       Impact factor: 3.390

7.  Facile synthesis of indole heterocyclic compounds based micellar nano anti-cancer drugs.

Authors:  Imran Ali; Sofi Danish Mukhtar; Ming Fa Hsieh; Zeid A Alothman; Abdulrahman Alwarthan
Journal:  RSC Adv       Date:  2018-11-13       Impact factor: 4.036

8.  Mitigating the Adverse Effects of Polychlorinated Biphenyl Derivatives on Estrogenic Activity via Molecular Modification Techniques.

Authors:  Wei He; Wenhui Zhang; Zhenhua Chu; Yu Li
Journal:  Int J Environ Res Public Health       Date:  2021-05-08       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.